{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Response was assessed by the International Myeloma Working Group (IMWG) response criteria, 2016. Complete Response is defined as negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in bone marrow aspirates. Stringent Complete Response is defined as complete response as noted previously plus normal free light chain (FLC) ratio and absence of clonal cells in bone marrow biopsy by immune-histochemistry.","dispersionType":"95% Confidence Interval","groups":[{"description":"Avelumab 800 mg IV every two weeks in combination with radiation therapy\n\nAvelumab: Avelumab 800 mg intravenous (IV) over 60 minutes (+/- 20 minutes) on days 1 and 15 of each 28-day cycle\n\nExternal beam radiotherapy: 5 gray (Gy) per fraction will be delivered on 5 consecutive treatment days for a total dose 25 Gy","id":"OG000","title":"1/Avelumab 800 mg Intravenous (IV) Every Two Weeks in Combination With Radiation Therapy"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"up to end of study for individual patient, an average of 11 months","title":"Fraction of Participants Who Experience a Complete Response (CR) or Stringent Complete Response (sCR) Using the Study Treatment","type":"SECONDARY","unitOfMeasure":"Proportion of participants"}